



Dr. Saltiki Katerina

Endocrinologist

Senior Scientific Associate, National and
Kapodistrian University of Athens (UoA)

Dr. Katerina Saltiki, MD, PhD, is a graduate of both the School of Medicine and the School of Pharmacy at the National and Kapodistrian University of Athens (UoA). She also holds a PhD from the UoA Medical School. As an undergraduate, she studied in France on a State Scholarships Foundation (IKY) grant. Her doctoral research focused on “the role of sex hormones and their receptors in women with coronary artery disease”.

She completed her specialty training in Endocrinology at the Therapeutic Clinic of UoA and the Endocrinology Department – Diabetes Center at Alexandra General Hospital.

Since 2006, Dr. Saltiki has served as a Scientific Associate, and for several years as Scientific and Clinical Lead at the Thyroid Neoplasia Outpatient Clinic of the endocrine, Diabetes & Metabolism Unit, Department of Clinical Therapeutics Athes University school of Medicine. She remains an active Senior Scientific Associate at the same clinic, focusing on thyroid neoplasms and associated genetic syndromes, as well as at the Unit for Clinical and Translational Research in Endocrinology, Athens University School of Medicine.

At the Thyroid Neoplasia Clinic, she has been involved in the clinical management of:

1. Over 300 patients with medullary thyroid carcinoma (MTC), both sporadic and familial (MEN 2A and MEN 2B syndromes), including more than 50 with metastatic disease; Over 100 patients carrying RET proto-oncogene mutations associated with hereditary MTC (MEN 2A and 2B)
2. Over 150 patients with radioiodine-refractory differentiated thyroid carcinoma, including more than 100 with metastatic disease
3. Family members of MEN 2A and MEN 2B *RET* carriers undergoing genetic counseling and long-term follow-up

Dr. Saltiki has conducted laboratory research at the Molecular Biology Lab of the Endocrinology Department at Alexandra Hospital, as well as at the Hormone Laboratory of the Endocrinology and Metabolism Research Unit at the Eugenides Foundation. She has also participated as a co-investigator in international multicenter clinical trials focused on treatments for metastatic thyroid cancer.

She has extensive teaching experience, particularly in thyroid cancer, educating undergraduate and postgraduate students, as well as endocrinology residents and specialists who have trained at the Thyroid Neoplasia Clinic.

Dr. Saltiki is the author of over 50 book chapters (in medical textbooks, academic publications in Greek and international literature), has published more than 50 peer-reviewed articles in high-impact international journals, and has contributed over 200 presentations to national and international medical congresses.

She has received more than twelve national and European awards for her scientific work. She is an active member of the European Society of Endocrinology (ESE), the European Thyroid Association (ETA), and the Hellenic Endocrine Society (HES). She is a frequent invited speaker, particularly in subjects related to advanced and aggressive thyroid cancer.

PUBLICATIONS:

1. **SALTIKI K, DOUKAS CH, KANAKAKIS J, ANASTASIOU E, MANTZOU E, ALEVIZAKI M.**

Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen.

Maturitas, 2006;55:51-57.

2. **ALEVIZAKI M, SALTIKI K, MANTZOU E, ANASTASIOU E, HUHTANIEMI I.**

The adrenal gland may be a target of LH action in postmenopausal women.

Eur J Endocrinol, 2006;154:875-881.

3. **SALTIKI K, ALEVIZAKI M.**

Coronary heart disease in postmenopausal women; The role of endogenous estrogens and their receptors.

Hormones, 2007;6:9-24.

4. **ALEVIZAKI M, SALTIKI K, XITA N, KANAKAKIS I, MANTZOU E, GEORGIOU I, SARIKA H-L.**

Severity of Cardiovascular Disease in Women: Associations with Common Estrogen Receptor Alpha Polymorphic Variants.

Eur J Endocrinol, 2007;56:489-496.

5. **ALEVIZAKI M, SALTIKI K, XITA N, CIMPONERIU A, STAMATELOPOULOS K, MANTZOU E, DOUKAS C, GEORGIOU I.**

The importance of the (TAAAA)n alleles at the SHBG gene promoter for the severity of coronary artery disease in postmenopausal women.

Menopause, 2008;15:461-8.

6. **SALTIKI K, VOIDONIKOLA P, STAMATELOPOULOS K, MANTZOU E, PAPAMICHAEL C, ALEVIZAKI M.**

Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: A cross-sectional study.

Thyroid Res, 2008 Sep 29;1(1):3.

7. **SALTIKI K, CIMPONERIU A, LILI K, PEPPA M, ANASTASIOU E, ALEVIZAKI M.**

Severity of coronary artery disease in postmenopausal diabetic women.

Hormones (Athens), 2008;7:148-155.

8. **ALEVIZAKI M, MANTZOU E, CIMPONERIU A, SALTIKI K, PHILIPPOU G, WIERSINGA W.**

The Pro(12)Ala PPARGgamma gene polymorphism: possible modifier of the activity and severity of thyroid associated orbitopathy (TAO).

Clin Endocrinol, 2009;70:464-8.

9. **SALTIKI K, MANTZOU E, DOUKAS C, KANAKAKIS I, LAZAROS L, GEORGIOU I, ALEVIZAKI M.**

Estrogen Receptor Beta Gene Variants may be Associated with More Favorable Metabolic Profile in Postmenopausal Women Undergoing Coronary Angiography.

Exp Clin Endocrinol Diabetes, 2009;117:610-615.

10. **DOUPIS J, STAVRIANOS CH, SALTIKI K, MANTZOU E, MASTROKOSTOPOULOS A, ALEVIZAKI M.**

Thyroid volume, selenium levels and nutritional habits in outpatients in southwestern Albania.

Hormones (Athens), 2009;8:296-302.

11. **ALEVIZAKI M, PAPAGEORGIOU G, RENTZIOU I, SALTIKI K, MARAFELIA P, LOUKARI E, KOUTRAS DA, DIMOPOULOS MA.**

Increasing prevalence of papillary thyroid carcinoma in recent years in Greeks: the majority are incidental.

Thyroid, 2009;19:749-54.

12. **ALEVIZAKI M, SALTIKI K, STAMATELOPOULOS K, VOIDONIKOLA P, MANTZOU E, PAPAMICHAEL CH.**

Free Thyroxin is an independent predictor of subcutaneous fat in euthyroid individuals.

Eur J Endocrinol, 2009;161:459-65.

13. **TERZIDIS K, PANOUTSOPOULOS A, MANTZOU A, TOURLI P, PAPAGEORGIOU G, SALTIKI K, MARA C, ALEVIZAKI M.**

Lower early morning plasma cortisol levels are associated with thyroid autoimmunity in the elderly
Eur J Endocrinol, 2010;162:307-13.

14. **K SALTIKI, G PAPAGEORGIOU, P VOIDONIKOLA, E MANTZOU, K XIROMERITIS, C PAPAMICHAEL, M ALEVIZAKI, K STAMATELOPOULOS.**

Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels

Endocrine, 2010;37:329-335.

15. **TERZIDIS K, PANOUTSOPOULOS A, MANTZOU A, TOURLI P, PAPAGEORGIOU G, SALTIKI K, TSAGALIS G, MARA C, ALEVIZAKI M.**

Cortisol levels and metabolic parameters in middle- and advanced- age subjects: associations with age

Journal of Endocrinological Investigation 2011;34:398-402

16. **KATERINA SALTIKI, ADRIANA CIMPONERIU, MARIA GAROFALAKI, LIDA SARIKA, ALEXANDRA PAPATHOMA, KIMON STAMATELOPOULOS, MARIA ALEVIZAKI**

Severity of coronary artery disease in women: association with the androgen receptor gene CAG(n) repeat polymorphism

Menopause 2011;18:1225-31

17. **ANASTASIOU E, VASILEIOY V, ATHANASIADOU A, STAVRIANOS C, SALTIKI K, ALEVIZAKI M**

Phenotypic and metabolic characteristics of women with isolated hyperglycemia in pregnancy. Is the time point important?

Diabetes Research and Clinical Practice, 2010; 90:333-8

18. TZANELA M, MANTZOU E, **SALTIKI K**, TAMPOURLOU M, KALOGERIS N, HADJIDAKIS D, TSAGARAKIS S, ALEVIZAKI M

Clinical and biochemical impact of BCL1 polymorphic genotype of the glucocorticoid receptor gene in patients with adrenal incidentalomas.

Journal of Endocrinological investigation 2012;35:395-400

19. PAPPA T, VEMMOS K, **SALTIKI K**, MANTZOU E, STAMATELOPOULOS K, ALEVIZAKI M

DHEAS: a biomarker of stroke severity and functional outcome in a female population suffering an acute stroke?

Metabolism 2012;61:84-91

20. **K SALTIKI**, K STAMATELOPOULOS, P VOIDONIKOLA, L LAZAROS, E MANTZOU, I GEORGIU, E ANASTASIOU, C PAPAMICHAEL, M ALEVIZAKI

Association of the SHBG gene promoter polymorphism with early markers of atherosclerosis in apparently healthy women

Atherosclerosis 2011;219:205-10.

21. H DOUKAS, **K SALTIKI**, K TERZIDIS, A MANTZOU, L SARIKA, A CIMPONERIU, P SFIKAKIS, M ALEVIZAKI

Hormonal parameters and sex hormone receptor gene polymorphisms in males with autoimmune diseases

Rheumatol Int. 2013;33:575-82

22. ALEVIZAKI M, **SALTIKI K**, RENTZIOU G, PAPATHOMA A, SARIKA L, VASILEIOU V, ANASTASIOU E.

Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression.

Eur J Endocrinol. 2012;167:799-808.

23. ALEVIZAKI M, KYRATZOGLOU E, BAMIAS A, TZANELA M, DIMOPOULOS MA, **SALTIKI K**.

Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Endocrine. 2013;44:610-5

24. RENTZIOU G, **SALTIKI K**, MANIOS E, STAMATELOPOULOS K, KOROBOKI E, VEMMOU A, MANTZOU E, ZAKOPOULOS N, ALEVIZAKI M.

Effects of recombinant human thyrotropin administration on 24-hour arterial pressure in female undergoing evaluation for differentiated thyroid cancer. Int J Endocrinol.

2014;2014:270213.

25. **SALTIKI K**, RENTZIOU G, STAMATELOPOULOS K, GEORGIPOULOS G, STAVRIANOS C, LAMBRINOUDAKI E, ALEVIZAKI M.

Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression.

Eur J Endocrinol. 2014;17:117-26.

26. GYFTAKI R, LIACOS C, POLITI E, LIONTOS M, **SALTIKI K**, PAPAGEORGIOU T, THOMAKOS N, HAIDOUPOULOS D, RODOLAKIS A, ALEVIZAKI M, BAMIAS A, DIMOPOULOS MA

Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.

Int J Gynecol Cancer. 2014;24:851-6

27. ALEVIZAKI M, **SALTIKI K**.

Primary hyperparathyroidism in MEN2 syndromes.

Recent Results Cancer Res. 2015;204:179-86

28. SARIKA HL, PAPATHOMA A, GAROFALAKI M, **SALTIKI K**, PAPPAS T, PAZAITOU-PANAYIOTOU K, ANASTASIOU E, ALEVIZAKI M.

Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.

Eur J Endocrinol. 2015;172:501-9

29. **K SALTIKI**, L SPANOY, M ALEVIZAKI

The utility of fine needle aspiration in the management of thyroid nodules

Hellenic Journal of Surgery, SPRINGER. 2015;87:14-17

30. GIANNAKOU M, **SALTIKI K**, MANTZOU E, LOUKARI E, PHILIPPOU G, TERZIDIS K, LILI K, STAVRIANOS C, KYPRIANOU M, ALEVIZAKI M

RAGE polymorphisms and oxidative stress levels in Hashimoto's thyroiditis.

Eur J Clin Invest. 2017;47:341-347

31. **SALTIKI KATERINA**, SIMEAKIS GEORGE, ANAGNOSTOU ELLI, ZAPANTI EVANGELIA, ANASTASIOU ELENI, ALEVIZAKI MARIA

Worse outcome in sporadic compared to familial medullary thyroid cancer despite similar stage at diagnosis

Head and Neck, 2019;41:154-161

32. KATERINA SALTIKI, ELLI ANAGNOSTOU, GEORGE SIMEAKIS, SOFIA KOUKI, ANASTASIA ANGELOPOULOU, LEDA SARIKA, ALEXANDRA PAPATHOMA, MARIA ALEVIZAKI

Familial MTC with ret exon 8 gly533cys mutation: origin and prevalence of second malignancy

Endocrine Connections 2017; 6:676-684

33. MARIA GIANNAKOU; **KATERINA SALTIKI**; EMILY MANTZOU; ELENI LOUKARI; GEORGIOS PHILIPPOU; KONSTANTINOS TERZIDIS; CHARALAMPOS STAVRIANOS; MILTIADES KYPRIANOU; THEODORA PSALTOPOULOU; MARIA ALEVIZAKI

The effect of obesity and dietary habits on oxidative stress in Hashimoto's thyroiditis

Endocrine Connections 2018; 7:990-997

34. OLGA KARAPANOU AND **KATERINA SALTIKI**, GEORGE SIMEAKIS, EFTHIMIA BOTOULA, STYLIANOS TSAGARAKIS, MARIA ALEVIZAKI AND BARBARA VLASSOPOULOU

Histology features are more important than persistently elevated anti-Tg antibodies for disease course in patients with differentiated thyroid cancer (DTC)

Clinical Endocrinology (Oxf). 2021;95:217-223

35. P. KAZAKOU, G. SIMEAKIS, M. ALEVIZAKI, **K. SALTIKI**

Unusual metastatic sites of medullary thyroid carcinoma; case reports

Endocrinol Diabetes Metab Case Rep. 2021:21-0063

36. **KATERINA SALTIKI¹, GEORGE SIMEAKIS^{2*} / OLGA KARAPANOU^{2*}, STAVROULA A PASCHOU¹, MARIA ALEVIZAKI¹**

Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance

Endocrine. 2023 Jun;80(3):570-579. doi: 10.1007/s12020-022-03296-1. Epub 2023 Jan 10. PMID: 36626081.

37. **KARAPANOU O, SIMEAKIS G, VLASSOPOULOU B, ALEVIZAKI M, SALTIKI K.**
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives.

Endocr Relat Cancer. 2022 Apr 22;29(5):R57-R66. doi: 10.1530/ERC-22-0006. PMID: 35266878.

38. **KATERINA SALTIKI, GEORGE SIMEAKIS, OLGA KARAPANOU, MARIA ALEVIZAKI**

Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.

Eur J Endocrinol. 2022;187: R53-R63.

39. **KANTREVA K, PASCHOU SA, STEFANAKI K, PAPPAS K, KAZAKOU P, VRACHNIS D, KAVOURA E, PAVLAKIS K, GIOVANNOPOULOU E, LATHOURAS K, ALEVIZAKI M, SALTIKI K.**

Two rare cases of benign struma ovarii with malignant recurrence.

Endocrinol Diabetes Metab Case Rep. 2024 Apr 12;2024(2):23-0122. doi: 10.1530/EDM-23-0122. PMID: 38614119; PMCID: PMC11046340.

40. **PASCHOU SA, BLETSAS E, SALTIKI K, KAZAKOU P, KANTREVA K, KATSAOUNOU P, ROVINA N, TRAKADA G, BAKAKOS P, VLACHOPOULOS CV, PSALTOPOULOU T.**
Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes.

Nutrients. 2022 Nov 24;14(23):4989. doi: 10.3390/nu14234989. PMID: 36501019; PMCID: PMC9741445.

41. **KANI ER, KARAVITI E, KARAVITI D, GERONTITI E, PASCHOU IA, SALTIKI K, STEFANAKI K, PSALTOPOULOU T, PASCHOU SA.**

Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus.

Endocrine. 2024 Sep 24. doi: 10.1007/s12020-024-04050-5. Epub 2024 Sep 24. PMID: 39316333.

42. **KANTREVA K, KATSAOUNOU P, SALTIKI K, TRAKADA G, NTALI G, STRATIGOU T, TZANELA M, PSALTOPOULOU T, PASCHOU SA.**

The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.

Endocrine. 2025 Feb;87(2):378-388. doi: 10.1007/s12020-024-04033-6. Epub 2024 Sep 17. PMID: 39289244.

43. **ARMENI AK, MARKANTES GK, STATHOPOULOU A, SALTIKI K, ZAMPAKIS P, ASSIMAKOPOULOS SF, MICHALAKI MA.**

Thyroid Eye Disease as Initial Manifestation of Graves' Disease Following Viral Vector SARS-CoV-2 Vaccine: Report of a Case and Review of the Literature.

Vaccines (Basel). 2023 Oct 10;11(10):1574. doi: 10.3390/vaccines11101574. PMID: 37896977; PMCID: PMC10611184.

44. **KATERINA SALTIKI**, OLGA KARAPANOU, KANELLA KANTREVA, MARINA MICHALAKI, KONSTANTINOS KOUTSOUKOS, STAVROULA A PASCHOU, MARIA ALEVIZAKI

Local treatments and TKI efficacy in radioiodine refractory differentiated thyroid carcinoma patients: a single center experience

Endocr Relat Cancer. 2025 Mar 1;32(4):e240024. doi: 10.1530/ERC-24-0024. PMID: 39970869.

45. PARASKEVI KAZAKOU, DIONYSIOS VRACHNIS, STAVROULA A. PASCHOU, KONSTANTINOS NASTOS, HELEN SARLANI, KANELLA KANTREVA, KATERINA STEFANAKI, THEODORA PSALTOPOULOU, GEORGE KYRIAKOPOULOS, PENELOPE KORKOLOPOULOU, **KATERINA SALTIKI**

An exceptionally rare case of a giant parathyroid adenoma with carcinoma features

Hormones (Athens). 2025 Jan 20. doi: 10.1007/s42000-025-00627-5.

46. ELENI SAZAKLI*, OLGA KARAPANOU*, GERASIMOS SYKIOTIS, **KATERINA SALTIKI** AND MARINA MICHALAKI

Exploring Adherence to the 2023 ETA Clinical Practice Guidelines for the Management of Thyroid Nodules with Indeterminate Cytology: A Nationwide Survey

Hormones (Athens) (in press)

47. GRIGORIS EFRAIMIDIS, ELENI SAZAKLI, OLGA KARAPANOU, **KATERINA SALTIKI** AND MARINA MICHALAKI

Active Surveillance for Papillary Thyroid Microcarcinoma: A Web-Survey on Clinician Readiness for Change.

Eur Thyroid J. 2025 Mar 17;14(2):e250013. doi: 10.1530/ETJ-25-0013. PMID: 40019776; PMCID: PMC11949526.

48. **SALTIKI K**, ALEVIZAKI M.

Primary Hyperparathyroidism in MEN2 Syndromes.

Recent Results Cancer Res. 2025;223:237-246. doi: 10.1007/978-3-031-80396-3_9. PMID: 40102260.

49. OLGA KARAPANOU, GRIGORIS EFFRAIMIDIS, EFFIE PETINELLIS, MARINA MICHALAKI, MILTIADIS KROKIDIS, **KATERINA SALTIKI**

Rare metastatic sites in three patients with RAI-refractory differentiated thyroid cancer (DTC) Hormones (Athens) 2025. doi: 10.1007/s42000-025-00694-8

50. GRIGORIS EFFRAIMIDIS, ELENI SAZAKLI, OLGA KARAPANOU, **KATERINA SALTIKI**, MARINA A. MICHALAKI

Management Preferences for Low and Low-to-Intermediate-Risk Papillary Thyroid Carcinoma Among Greek Endocrinologists: Insights from a Web-Based Survey (manuscript submitted)

51. GRIGORIS EFFRAIMIDIS, ATHANASIOS KASOTAS, ELENI SAZAKLI, OLGA KARAPANOU, **KATERINA SALTIKI** AND MARINA MICHALAKI

AI Chatbots vs Endocrinologists in Clinical Decision-Making in Thyroid Nodule and Papillary Thyroid Carcinoma Management (manuscript under revision)